Analysts Expect XOMA Corp (XOMA) to Post -$0.22 Earnings Per Share

Wall Street brokerages expect XOMA Corp (NASDAQ:XOMA) to report earnings per share of ($0.22) for the current quarter, according to Zacks. Two analysts have issued estimates for XOMA’s earnings, with the highest EPS estimate coming in at ($0.08) and the lowest estimate coming in at ($0.35). XOMA reported earnings per share of $1.98 in the same quarter last year, which would suggest a negative year over year growth rate of 111.1%. The company is scheduled to issue its next earnings report on Monday, November 5th.

On average, analysts expect that XOMA will report full year earnings of ($0.79) per share for the current financial year, with EPS estimates ranging from ($0.85) to ($0.66). For the next financial year, analysts expect that the firm will report earnings of ($0.59) per share, with EPS estimates ranging from ($0.84) to ($0.27). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover XOMA.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.03). XOMA had a negative return on equity of 670.15% and a net margin of 40.44%. The firm had revenue of $2.26 million during the quarter, compared to analysts’ expectations of $4.57 million.

A number of brokerages have commented on XOMA. Zacks Investment Research downgraded shares of XOMA from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 10th. TheStreet upgraded shares of XOMA from a “d” rating to a “c-” rating in a research note on Tuesday, June 12th. Cowen restated a “hold” rating on shares of XOMA in a research note on Thursday, May 10th. HC Wainwright set a $49.00 price objective on shares of XOMA and gave the company a “buy” rating in a research note on Monday, April 30th. Finally, Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of XOMA in a research note on Wednesday. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. XOMA presently has an average rating of “Hold” and an average price target of $36.33.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its position in XOMA by 4,288.9% during the fourth quarter. Wells Fargo & Company MN now owns 8,295 shares of the biotechnology company’s stock valued at $295,000 after acquiring an additional 8,106 shares during the last quarter. Geode Capital Management LLC raised its stake in XOMA by 40.9% during the fourth quarter. Geode Capital Management LLC now owns 61,281 shares of the biotechnology company’s stock worth $2,180,000 after purchasing an additional 17,790 shares during the period. Goldman Sachs Group Inc. purchased a new position in XOMA during the fourth quarter worth about $328,000. Two Sigma Advisers LP purchased a new position in XOMA during the fourth quarter worth about $464,000. Finally, Millennium Management LLC raised its stake in XOMA by 1,404.7% during the fourth quarter. Millennium Management LLC now owns 196,759 shares of the biotechnology company’s stock worth $7,005,000 after purchasing an additional 183,683 shares during the period. Hedge funds and other institutional investors own 41.05% of the company’s stock.

Shares of XOMA opened at $19.30 on Monday, Marketbeat reports. The company has a debt-to-equity ratio of 2.59, a quick ratio of 7.26 and a current ratio of 7.26. The stock has a market capitalization of $202.27 million, a price-to-earnings ratio of 19.69 and a beta of 2.64. XOMA has a one year low of $7.07 and a one year high of $37.25.

XOMA Company Profile

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.

See Also: What is a Leveraged Buyout (LBO)?

Get a free copy of the Zacks research report on XOMA (XOMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply